Skip NavigationSkip to Content
Return Return to Search Results

A Phase Ii Study of Carboplatin, Cisplatin, Interferon-Alpha, and Tamoxifen For Patients With Metastatic Melanoma

  1. Author:
    Gause, B. L.
    Sharfman, W. H.
    Janik, J. E.
    Curti, B. D.
    Steis, R. G.
    Urba, W. J.
    Smith, J. W.
    Alvord, W. G.
    Longo, S. L.
    1. Year: 1998
  2. Journal: Cancer Investigation
    1. 16
    2. 6
    3. Pages: 374-380
  4. Type of Article: Article
  1. Abstract:

    The purpose of this trial was to determine the toxicity and antineoplastic activity of cisplatin, carboplatin, tamoxifen, and interferon-alpha (IFN-alpha) in patients with advanced melanoma. Eleven patients with metastatic melanoma,were enrolled. The patients received carboplatin 400 mg/m(2) IV on day 0; cisplatin 25 mg/m(2) IV on clays 7, 14 and 21; tamoxifen 20 mg p.o. b.i.d. on days 0-27; and interferon-alpha 5 million units/m(2) subcutaneously 3 times per week. Cycles were repeated every 28 days. Patients were assessed for tumor response at the end of 2 cycles. Toxicity was severe, with 14 of 24 cycles given requiring some form of dose reduction. Carboplatin dose reductions were related to bone-marrow toxicity whereas IFN-alpha caused fatigue, arthralgias, myalgias, and fever. The overall response rate was 18% (2 partial responses [PRs]). The combination of cisplatin, carboplatin, tamoxifen, and IFN-alpha is active in advanced melanoma; however the toxicity is unacceptable. [References: 28]

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel